The data from our current study showed that the inclusion of myeloid lineage-associated markers, such as CD13, CD64, CD36, CD105, CD71, and CD33, in the gating strategy can increase the discriminatory power for distinguishing between AML blasts and normal HPCs that are committed toward different myeloid lineages. Here, CD33 is linked to acute myeloid leukemia.